Ana Fernández-Marmiesse1,2, Hirofumi Kusumoto3, Saray Rekarte4, Iria Roca1,2, Jin Zhang3,5, Scott J Myers3,6, Stephen F Traynelis3,6, Mª Luz Couce1,2, Luis Gutierrez-Solana4, Hongjie Yuan3,6. 1. Unit for the Diagnosis and Treatment of Congenital Metabolic Diseases, Clinical University Hospital of Santiago de Compostela, Health Research Institute of Santiago de Compostela, Santiago de Compostela, Galicia, Spain. 2. Centro de Investigación Biomédica de Enfermedades Raras, Instituto de Salud Carlos III, Madrid, Spain. 3. Department of Pharmacology, Emory University School of Medicine, Rollins Research Center, Atlanta, Georgia, USA. 4. Unit of Child Neurology, Department of Pediatrics, Hospital Infantil Universitario Niño Jesús de Madrid, Madrid, Spain. 5. Department of Neurology, the First Hospital of Shanxi Medical University, Taiyuan, China. 6. Center for Functional Evaluation of Rare Variants, Emory University School of Medicine, Atlanta, Georgia, USA.
Abstract
BACKGROUND: Mutations in the GRIN2A gene, which encodes the GluN2A (glutamate [NMDA] receptor subunit epsilon-1) subunit of the N-methyl-d-aspartate receptor, have been identified in patients with epilepsy-aphasia spectrum disorders, idiopathic focal epilepsies with centrotemporal spikes, and epileptic encephalopathies with severe developmental delay. However, thus far, mutations in this gene have not been associated with a nonepileptic neurodevelopmental disorder with dystonia. OBJECTIVES: The objective of this study was to identify the disease-causing gene in 2 siblings with neurodevelopmental and movement disorders with no epileptiform abnormalities. METHODS: The study method was targeted next-generation sequencing panel for neuropediatric disorders and subsequent electrophysiological studies. RESULTS: The 2 siblings carry a novel missense mutation in the GRIN2A gene (p.Ala643Asp) that was not detected in genomic DNA isolated from blood cells of their parents, suggesting that the mutation is the consequence of germinal mosaicism in 1 progenitor. In functional studies, the GluN2A-A643D mutation increased the potency of the agonists L-glutamate and glycine and decreased the potency of endogenous negative modulators, including protons, magnesium and zinc but reduced agonist-evoked peak current response in mammalian cells, suggesting that this mutation has a mixed effect on N-methyl-d-aspartate receptor function. CONCLUSION: De novo GRIN2A mutations can give rise to a neurodevelopmental and movement disorder without epilepsy.
BACKGROUND: Mutations in the GRIN2A gene, which encodes the GluN2A (glutamate [NMDA] receptor subunit epsilon-1) subunit of the N-methyl-d-aspartate receptor, have been identified in patients with epilepsy-aphasia spectrum disorders, idiopathic focal epilepsies with centrotemporal spikes, and epilepticencephalopathies with severe developmental delay. However, thus far, mutations in this gene have not been associated with a nonepileptic neurodevelopmental disorder with dystonia. OBJECTIVES: The objective of this study was to identify the disease-causing gene in 2 siblings with neurodevelopmental and movement disorders with no epileptiform abnormalities. METHODS: The study method was targeted next-generation sequencing panel for neuropediatric disorders and subsequent electrophysiological studies. RESULTS: The 2 siblings carry a novel missense mutation in the GRIN2A gene (p.Ala643Asp) that was not detected in genomic DNA isolated from blood cells of their parents, suggesting that the mutation is the consequence of germinal mosaicism in 1 progenitor. In functional studies, the GluN2A-A643D mutation increased the potency of the agonists L-glutamate and glycine and decreased the potency of endogenous negative modulators, including protons, magnesium and zinc but reduced agonist-evoked peak current response in mammalian cells, suggesting that this mutation has a mixed effect on N-methyl-d-aspartate receptor function. CONCLUSION: De novo GRIN2A mutations can give rise to a neurodevelopmental and movement disorder without epilepsy.
Authors: Stephen F Traynelis; Lonnie P Wollmuth; Chris J McBain; Frank S Menniti; Katie M Vance; Kevin K Ogden; Kasper B Hansen; Hongjie Yuan; Scott J Myers; Ray Dingledine Journal: Pharmacol Rev Date: 2010-09 Impact factor: 25.468
Authors: Sunita Venkateswaran; Ken A Myers; Amanda C Smith; Chandree L Beaulieu; Jeremy A Schwartzentruber; Jacek Majewski; Dennis Bulman; Kym M Boycott; David A Dyment Journal: Epilepsia Date: 2014-06-05 Impact factor: 5.864
Authors: J Tarabeux; O Kebir; J Gauthier; F F Hamdan; L Xiong; A Piton; D Spiegelman; É Henrion; B Millet; F Fathalli; R Joober; J L Rapoport; L E DeLisi; É Fombonne; L Mottron; N Forget-Dubois; M Boivin; J L Michaud; P Drapeau; R G Lafrenière; G A Rouleau; M-O Krebs Journal: Transl Psychiatry Date: 2011-11-15 Impact factor: 6.222
Authors: Brian J O'Roak; Pelagia Deriziotis; Choli Lee; Laura Vives; Jerrod J Schwartz; Santhosh Girirajan; Emre Karakoc; Alexandra P Mackenzie; Sarah B Ng; Carl Baker; Mark J Rieder; Deborah A Nickerson; Raphael Bernier; Simon E Fisher; Jay Shendure; Evan E Eichler Journal: Nat Genet Date: 2011-05-15 Impact factor: 38.330
Authors: Gemma L Carvill; Brigid M Regan; Simone C Yendle; Brian J O'Roak; Natalia Lozovaya; Nadine Bruneau; Nail Burnashev; Adiba Khan; Joseph Cook; Eileen Geraghty; Lynette G Sadleir; Samantha J Turner; Meng-Han Tsai; Richard Webster; Robert Ouvrier; John A Damiano; Samuel F Berkovic; Jay Shendure; Michael S Hildebrand; Pierre Szepetowski; Ingrid E Scheffer; Heather C Mefford Journal: Nat Genet Date: 2013-08-11 Impact factor: 38.330
Authors: Kasper B Hansen; Lonnie P Wollmuth; Derek Bowie; Hiro Furukawa; Frank S Menniti; Alexander I Sobolevsky; Geoffrey T Swanson; Sharon A Swanger; Ingo H Greger; Terunaga Nakagawa; Chris J McBain; Vasanthi Jayaraman; Chian-Ming Low; Mark L Dell'Acqua; Jeffrey S Diamond; Chad R Camp; Riley E Perszyk; Hongjie Yuan; Stephen F Traynelis Journal: Pharmacol Rev Date: 2021-10 Impact factor: 18.923
Authors: Riley E Perszyk; Scott J Myers; Hongjie Yuan; Alasdair J Gibb; Hiro Furukawa; Alexander I Sobolevsky; Stephen F Traynelis Journal: J Physiol Date: 2020-06-15 Impact factor: 5.182
Authors: Katie F M Marwick; Kasper B Hansen; Paul A Skehel; Giles E Hardingham; David J A Wyllie Journal: J Physiol Date: 2019-01-30 Impact factor: 5.182